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OBJECTIVES: Estimate the cost of an asthma exacerba-
tion and its management in the hospital setting in Spain.
METHODS: Prospective observational study conducted
in six Spanish hospitals during 2000 on 126 patients suf-
fering an asthma exacerbation, who were treated rou-
tinely. Both direct and indirect costs of each episode were
calculated. RESULTS: Forty-two (33.3%) of the exacer-
bations were mild, 49 (38.9%) moderate, 33 (26.2%)
severe and 2 (1.6%) had risk of imminent respiratory
arrest (IRA). Twenty-four percent of the severe exacer-
bations occurred in patients with a diagnosis of intermit-
tent mild asthma. The most frequently prescribed drugs
to treat exacerbations were oral corticosteroids and short-
acting beta-2-agonists and those most frequently used
before the exacerbation were short-acting beta-2-agonists
and inhaled corticosteroids. An average of 8.1 diagnostic
tests were conducted to resolve an exacerbation. The
average cost of an attack was €1555.7 (CI 95%
1237.6–1907). Costs increased with the severity of the
attack, the cost of a mild attack being €292.6 (CI 95%
176–452.4), moderate €1230.5, (CI 95% 860.6–1605.8),
and severe €3543.1, (CI 95% 2908.7–4191.3). The cost
of an IRA episode was less than that of a severe attack:
€3255.7 (CI 95% 1188.2–5323.2). Direct costs repre-
sented 93.9% of the total cost (indirect costs 6.11%);
costs arising from hospitalisation, transport, and re-
admission accounted for 82.6% and medication 5.9% of
the direct costs. CONCLUSIONS: Although the drugs
used for both management and prevention of asthma
exacerbations are correct, the fact that moderate and/or
severe exacerbations are a majority suggests that either
preventive treatment was inadequate for the degree of
asthma prior to the exacerbation or there was non-
adherence to treatment. The cost of an asthma attack
treated in the hospital setting is high, (€1555.7 CI 95%
1237.6–1907), largely due to hospitalisation, transport,
and readmission costs.
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A CROSS-SECTIONAL, OBSERVATIONAL STUDY
TO ESTABLISH THE RESOURCES AND COSTS
ASSOCIATED WITH CONTROLLED AND
POORLY CONTROLLED MODERATE TO SEVERE
ASTHMA PATIENTS IN THE UK
Ossa DF1, Brown R1, Price D2, Everhard F3
1MEDTAP International, London, United Kingdom; 2University
of Aberdeen, Aberdeen, United Kingdom; 3Novartis
Pharmaceuticals AG, Basel, Switzerland
OBJECTIVE: Resource utilisation by asthma patients is
greater than non-asthmatic patients and increases with
disease severity, but little information exists on asthma
costs by control status of the disease. The objective is to
estimate the costs associated with controlled and poorly
controlled moderate to severe asthma patients in the UK.
METHODS: A cross-sectional, observational study was
performed in three UK sites to capture resource use by
the deﬁned population. Data on demographics, clinical
history, disease characteristics, and direct Health care
resource utilisation was captured retrospectively over a 1-
year period. Prospective health resource utilisation data
were collected over 4 weeks, including productivity losses
for patient or caregiver, using patient diaries. All relevant
variables were summarised and analysed using descriptive
statistics by entire population and grouped by severity
with poorly controlled deﬁned as oral steroid use and
unscheduled GP/emergency visit or a hospital admission
for asthma in the preceding year. RESULTS: There were
274 retrospective patients: 214 were controlled and 60
were poorly controlled with annual average direct
medical costs of £369 (95% CI: £259–£517) and £873
(95% CI: £492–£1392), respectively. Prospective data
were collected on 80 patients: 72 controlled and 8 poorly
controlled. Monthly average costs per patient in the con-
trolled group were £176 (95% CI: £87–£297), of which
£64 (95% CI: £19–£116) were indirect costs. In the
poorly controlled group, monthly average costs per
patient were £2,731 (95% CI: £1242–£4735) of which
£998 (95% CI: £395–£1663) were indirect costs. CON-
CLUSIONS: Although the poorly controlled groups were
small, results suggest that improving asthma control in
those poorly controlled will decrease health care and soci-
etal costs as well as patient morbidity.
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OBJECTIVE: to compare costs and effects of salme-
terol/ﬂuticasone propionate combination (SFC) 50/250mg
bd with formoterol (12mg bd) and budesonide (800mg
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bd) (Form + Bud) given concurrently in adult patients
with moderate-to-severe asthma. METHODS: The
Markov model for the Polish Health care context was
based on clinical data from the literature (data from ran-
domised, double blind head-to-head comparison of SFC
and Form + Bud treatments in adults) and local data on
Health care resource utilisation and unit costs. Given
their clinical and economic importance, asthma exacer-
bations were a central consideration in the development
of the model. The outcome measure was number of suc-
cessfully controlled weeks (SCW) during the study period.
Only direct medical costs were analysed. The payer’s per-
spective and time horizon of 12 weeks were adopted.
Probabilistic sensitivity analysis was used to examine the
uncertainty in the cost-effectiveness results. It was
assumed that price of SFC is equal its components prices.
RESULTS: Running the model over 12-week period using
transition probabilities derived from RCT demonstrated
that treatment with SFC in comparison to the treatment
with Form + Bud resulted in a higher proportion of SCW
per patient (2.68 [CI 95%: 2.29–3.13] vs. 2.44 [CI 95%:
2.05–2.85]). SFC was also the less costly treatment, due
primarily to lower hospitalization and drug costs. Mean
weekly direct asthma management costs was 58.39 PLN
(CI 95%: 53.54–65.36) in SFC per treated patient and
72.42 PLN (CI 95%: 66.94–80.39) per Form + Bud
treated patient. Probabilistic sensitivity analysis showed
that in all cases SFC was the dominant strategy (more
effective and less costly). CONCLUSION: Since SFC
resulted in a better effect at a lower cost, this strategy 
was considered to be dominant for Polish patients with
moderate-to-severe asthma.
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OBJECTIVE: Asthma ranks ﬁrst among serious chronic
diseases affecting children and is reported to be the third
leading cause of hospitalization for children. This study
examines the resource use and costs of hospital care for
children and adolescents (age <= 17 years) admitted for
asthma in California and Massachusetts. METHODS:
Patient-level 2000 hospital discharge data from both
states were examined using ICD-9 diagnosis codes
(493.00–493.02, 493.90–493.92) to identify those admit-
ted with a principal diagnosis of asthma. These databases
were used to examine demographics and to develop hos-
pital costs, length of stay (LOS), physician visit proﬁles,
dispositions, and readmissions. Cost estimates include
accommodations, ancillary and physician services and are
reported in 2003 US$. Hospital charges were adjusted by
means of a 0.61 cost-to-charge ratio. RESULTS: Of the
10,488 cases identiﬁed: 59% were male; mean age was
6.6 years (median: 5.5, 79% were <=10 years); 51% were
admitted through Emergency Room, and 13% spent time
in special care units. Race/ethnicity was reported as 
Hispanic for the majority of patients (37%), followed 
by white (27%), black (27%), Asian (5%), and Other/
Unknown (4%). Mean LOS was 2.4 days (median: 2,
range: 1–142). Mean cost per stay was $5,045 (median:
$3,319, range: $194–$687,177). Hospital case fatality
rate was <1%. Among survivors, >99% went home,
1.5% with home health care. Most patients (89%) had
only 1 admission during the year; however 11% had at
least 1 readmission (range: 1–9). Managed care organi-
zations were the responsible payer for most cases (63%),
followed by Medicaid (27%). CONCLUSIONS: The cost
of a hospital stay is considerable and represents a sub-
stantial economic consequence of asthma. The majority
of patients were recorded as Hispanic, however, this is
likely a reﬂection of the states used and should not be
interpreted as increased frequency of asthma in Hispanic
children overall.
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OBJECTIVE: To compare the feasibility, reliability, valid-
ity and sensitivity to change of the Spanish version of the
Juniper Quality of Life Questionnaire (AQLQ), Juniper
Mini Asthma Quality of Life Questionnaire (Mini-
AQLQ) and Marks Asthma Quality of Life Questionnaire
(Marks-AQLQ) for use in clinical practice. METHODS:
Eight hundred seventy-eight patients, with a diagnosis of
mild to moderate asthma, were randomly assigned to
receive one of the 3 questionnaires. Montelukast was
added to the patients with uncontrolled asthma. Feasibil-
ity was assessed using mean time of administration and
percentage of missing responses. Internal consistency and
reliability was assessed using Cronbach’s alpha and the
intraclass correlation coefﬁcient (ICC). Construct validity
was assessed by correlating questionnaire scores with
EuroQoL-5D scores and symptoms. Responsiveness was
assessed by calculating the standardized effect size (SES).
RESULTS: Mean administration time was 7, 8 and 13
minutes for Mini-AQLQ, Marks-AQLQ and AQLQ
respectively. On the Mini-AQLQ and Marks-AQLQ 3.3
and 3.8% patients had missing responses compared with
11.1% on the AQLQ. For Mini-AQLQ, Marks-AQLQ
and AQLQ Cronbach’s alpha were 0.85, 0.90 and 0.91
respectively and ICC were 0.63, 0.74 and 0.78. In uni-
